Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures [Phase 3]
A Phase 3 long-term safety and tolerability study of lacosamide as monotherapy in adults with partial-onset seizures has completed with resu…
-
FDA approval · 2019-06-28FDA Approved: CLONAZEPAM — Original Application (Alembic Pharmaceuticals Inc.)
The FDA approved Alembic Pharmaceuticals' original application for a generic clonazepam product, expanding access to the generic formulation…
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: RNS® System LTT Study [Phase 4]
Phase 4 trial update for the RNS System LTT study in epilepsy has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-25Clinical Trial Update: Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters [Phase 3]
Phase 3 trial evaluating long-term safety and tolerability of USL261 in patients with seizure clusters was terminated; results posted in 201…
-
FDA approval · 2019-06-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Vimpat (lacosamide) submitted by UCB, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-06-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The supplement likely updates the product labeling or…
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method [Phase 3]
Phase 3 follow-up open-label study of levetiracetam for partial-onset seizures in epilepsy; results posted after completion.
-
CLINICAL_TRIALS research · 2019-06-04Clinical Trial Update: Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults [Phase 4]
A Phase 4 trial comparing cognitive and behavioral effects of eslicarbazepine acetate vs. carbamazepine in healthy adults to assess tolerabi…
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters [Phase 3]
Phase 3 trial evaluating intranasal midazolam (USL261) for seizure clusters in epilepsy was terminated; results posted in 2019.
-
FDA approval · 2019-05-31FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for Sabril (vigabatrin) from Lundbeck Pharmaceuticals LLC. The action completes an approved suppleme…
-
FDA approval · 2019-05-30FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved Eisai's supplemental application for FYCOMPA (perampanel), expanding the drug's labeled uses.
-
FDA approval · 2019-05-30FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved Eisai's supplemental application for FYCOMPA (perampanel), marking an approval of changes to the product's labeling related…
-
FDA approval · 2019-05-30FDA Approved: VIGABATRIN — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for Vigabatrin filed by Par Health USA, LLC.
-
FDA approval · 2019-05-30FDA Approved: VIGABATRIN — Supplemental Application (Dr. Reddys Laboratories Inc.,)
FDA approved a supplemental application for Vigabatrin from Dr. Reddy's Laboratories Inc., marking an approval related to a generic Vigabatr…
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting [Phase 2]
Phase 2 trial evaluating brivaracetam for increased seizure activity in an epilepsy monitoring unit; study completed with results posted.
-
FDA approval · 2019-05-17FDA Approved: NAYZILAM — Original Application (UCB, Inc.)
The FDA approved Nayzilam, a nasal spray form of midazolam, under an original NDA for the acute treatment of seizures in people with epileps…
-
CLINICAL_TRIALS trial_result · 2019-05-15Clinical Trial Update: A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents [Phase 2]
Phase 2 open-label extension study evaluating perampanel (E2007) in adolescents with epilepsy, focusing on cognition, growth, safety, tolera…
-
CLINICAL_TRIALS trial_result · 2019-05-15Clinical Trial Update: BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients [Phase 4]
Phase 4 clinical trial evaluating the repeatability of lamotrigine pharmacokinetics in patients with epilepsy has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. [Phase 2]
Phase 2 trial evaluating lacosamide added to current therapy in children with epilepsy syndromes presenting generalized seizures; results po…
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With Epilepsy [NA]
A terminated clinical trial investigating vagus nerve neurostimulation for reducing seizure frequency in epilepsy has posted results.
-
CLINICAL_TRIALS trial_result · 2019-04-22Clinical Trial Update: A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures [Phase 3]
A long-term Phase 3 study assessing safety, tolerability, and efficacy of retigabine IR in Asian adults with partial onset seizures has comp…
-
FDA approval · 2019-04-15FDA Approved: CLOBAZAM — Original Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approves CLOBAZAM as an original ANDA for a generic clobazam product from Taro Pharmaceuticals U.S.A., Inc.
-
CLINICAL_TRIALS trial_result · 2019-03-29Clinical Trial Update: Voronistat in Pediatric Patients With Drug Resistant Epilepsy [Phase 2]
Phase 2 clinical trial update for voronistat in pediatric patients with drug-resistant epilepsy.
-
CLINICAL_TRIALS research · 2019-02-22Clinical Trial Update: Laryngeal Motor Evoked-potentials as a Biomarker of Vagus Nerve Stimulation in Epileptic Patients [NA]
A clinical trial update examining whether laryngeal motor evoked potentials can serve as a biomarker for vagus nerve stimulation in adults w…
-
FDA approval · 2019-02-21FDA Approved: TROKENDI XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for TROKENDI XR (topiramate) from Supernus Pharmaceuticals, authorizing an update to the product via…